Martin Reck

Martin Reck, MD, PhD, is Head of the Thoracic Oncology Department at LungenClinic Grosshansdorf and a leading investigator within the German Center for Lung Research (DZL). He is globally recognized as the principal investigator of the KEYNOTE-024 trial, the landmark phase III study that established pembrolizumab monotherapy as the standard first-line treatment for metastatic NSCLC with PD-L1 tumor proportion score (TPS) ≥50%, fundamentally redefining front-line management of advanced lung cancer. Reck has led or co-led multiple pivotal immunotherapy trials including KEYNOTE-189 and KEYNOTE-407, which extended first-line pembrolizumab-based chemo-immunotherapy combinations to non-squamous and squamous NSCLC populations regardless of PD-L1 expression. His work on long-term survival follow-up from KEYNOTE-024 documented unprecedented 5-year overall survival rates approaching 32% in the PD-L1 high population, providing durable benefit data that transformed oncologist confidence in checkpoint inhibitors. Beyond trial leadership, Reck is an internationally sought lecturer on immunotherapy sequencing, predictive biomarker interpretation, and treatment strategies in lung cancer. He has served on numerous ESMO and IASLC guideline committees and mentored a generation of European thoracic oncologists. His integrative research approach combining clinical trial execution with translational biomarker science places him among the most impactful figures in modern thoracic oncology.